Eli Lilly and Company

Therapeutic antibodies for COVID-19

Eli Lilly and Company received foundation support to facilitate access to future Lilly therapeutic antibodies under development for the prevention and treatment of COVID-19 in low- and middle-income countries as part of the COVID-19 Therapeutics Accelerator. The antibodies will be manufactured at FUJIFILM Diosynth Biotechnologies facility in Denmark.
  • Domain
  • Investment type
    Volume guarantee
  • Status
  • Initial investment
  • Partnered in
  • Investment lead
    Ryan Kreitzer
  • Headquarters
  • Program strategy
    COVID-19 Response

More about our work

Our focus

Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.

Investment approach

Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.

Our team

We bring depth of experience to every investment, with a proven track record across sectors and scale.